{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-014884","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.050270+00:00","generated_at":"2026-06-18T23:13:55.506499+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Oramed Pharmaceuticals adopts amended bylaws with new stockholder consent rules and indemnification limits","bullets":["Board adopted Fourth Amended and Restated By-laws effective February 23, 2023.","New rules for stockholder action by written consent, including record date and independent inspector of election.","Limits indemnification for proceedings commenced by the person unless board-authorized.","Reduces indemnification by amounts collected from other entity for service at another entity.","Requires affirmative vote of majority of outstanding shares to alter, amend, or repeal bylaws."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-014884","json":"https://secwatch.observer/filing/0001213900-23-014884.json","markdown":"https://secwatch.observer/filing/0001213900-23-014884.md","text":"https://secwatch.observer/filing/0001213900-23-014884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023014884/0001213900-23-014884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023014884/ea174308-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:13:55.506499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7389c8646d634ddb2cdf0557bfa5e89f92530074","claim":"ORAMED PHARMACEUTICALS INC.: Adopted Fourth Amended and Restated By-laws implementing rules for stockholder action by written consent, eliminating outdated provisions, limiting indemnification, and requiring majority vote for amendments (effective 2023-02-23).","evidence_excerpt":"On February 23, 2023, the board of directors of Oramed Pharmaceuticals Inc. (the “Company”) adopted Fourth Amended and Restated By-laws (the “By-laws”), which became effective immediately","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023014884/0001213900-23-014884-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-23"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}